帕利哌酮缓释片改善精神分裂症患者社会功能的疗效：一项随机对照研究

[Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study].

作者信息

Wang Yang, Li Wan-shun, Gu De-kang, Yang Nan, Lu Yi, Zhang Yan, Cao Yu, Bai Lu-dong

机构信息

Department of Psychiatry, School of Medicine, Shandong University, Jinan 250012, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2010 Aug 3;90(29):2030-5.

PMID:21029638

Abstract

OBJECTIVE

To explore the efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics.

METHODS

A total of 81 schizophrenics were randomly divided into study group with paliperidone extended-release tablets and control group with risperidone for a 12-week treatment. They were assessed and analyzed by positive and negative symptoms scales (PANSS), social disability screening schedule (SDSS) and treatment emergent symptom scale (TESS) at baseline, 6(th) weekend and 12(th) weekend.

RESULTS

In study group, the factors and total scores of PANSS in the 12(th) weekend of treatment [(12.0 ± 2.8), (12.1 ± 3.6), (26.2 ± 5.0), (50.2 ± 8.7)] were all significantly lower than those at baseline [(24.7 ± 5.3), (23.8 ± 3.6), (45.0 ± 2.9), (93.5 ± 6.8)] (t = 9.60-16.78, P < 0.05). In study group, the positive factor, negative factor and total scores of PANSS in the 12(th) weekend of treatment [(12.0 ± 2.8), (12.1 ± 3.6), (50.2 ± 8.7)] were all significantly lower than those in the 6(th) weekend of treatment [(14.2 ± 1.8), (14.6 ± 2.4), (56.5 ± 6.4)] (t = 2.58-4.26, P < 0.05). In the 12(th) weekend of treatment, the factors and total scores of PANSS in study group [(12.0 ± 2.8), (12.1 ± 3.6), (26.2 ± 5.0), (50.2 ± 8.7)] were all significantly lower than those in control group [(16.9 ± 4.9), (18.7 ± 5.3), (32.5 ± 5.1), (68.1 ± 13.0)] (t = -4.28--5.67, P < 0.05). In study group, the total scores of SDSS in the 12(th) weekend of treatment (5.93 ± 2.78) were significantly lower than those at baseline (13.9 ± 3.4) (t = 10.83, P < 0.05). In study group, the total scores of SDSS in the 12(th) weekend of treatment (5.9 ± 2.8) were significantly lower than those in the 6(th) weekend of treatment (7.6 ± 2.9) (t = 5.21, P < 0.05). But there was no significant improvement in control group (t = 1.88, P > 0.05). In the 12(th) weekend of treatment, the total scores of SDSS in study group (5.9 ± 2.8) were significantly lower than those in control group (8.8 ± 2.9) (t = -4.49, P < 0.05). No severe adverse effect was reported in either group.

CONCLUSION

Paliperidone extended-release tablets are effective to improve social functions and psychiatric symptoms of schizophrenics.

摘要

目的

探讨帕利哌酮缓释片对改善精神分裂症患者社会功能的疗效。

方法

将81例精神分裂症患者随机分为帕利哌酮缓释片治疗组和利培酮对照组，进行为期12周的治疗。在基线期、第6周末和第12周末采用阳性与阴性症状量表（PANSS）、社会功能缺陷筛选量表（SDSS）及治疗中出现的症状量表（TESS）进行评定分析。

结果

治疗组治疗12周末PANSS各因子分及总分[（12.0±2.8），（12.1±3.6），（26.2±5.0），（50.2±8.7）]均显著低于基线期[（24.7±5.3），（23.8±3.6），（45.0±2.9），（93.5±6.8）]（t=9.60～16.78，P<0.05）。治疗组治疗12周末PANSS阳性因子分、阴性因子分及总分[（12.0±2.8），（12.1±3.6），（50.2±8.7）]均显著低于治疗6周末[（14.2±1.8），（14.6±2.4），（56.5±6.4）]（t=2.58～4.26，P<0.05）。治疗12周末，治疗组PANSS各因子分及总分[（12.0±2.8），（12.1±3.6），（26.2±5.0），（50.2±8.7）]均显著低于对照组[（16.9±4.9），（18.7±5.3），（32.5±5.1），（68.1±13.0）]（t=-4.28～-5.67，P<0.05）。治疗组治疗12周末SDSS总分（5.93±2.78）显著低于基线期（13.9±3.4）（t=10.83，P<0.05）。治疗组治疗12周末SDSS总分（5.9±2.8）显著低于治疗6周末（7.6±2.9）（t=5.21，P<0.05）。而对照组无明显改善（t=1.88，P>0.05）。治疗12周末，治疗组SDSS总分（5.9±2.8）显著低于对照组（8.8±2.9）（t=-4.49，P<0.05）。两组均未报告严重不良反应。